Key features and details
- Negative control for clathrin inhibitor Pitstop® 1 (ab120685)
- Purity: > 98%
- Soluble in DMSO to 100mM and in water to 25mM
- Form / State: Solid
- Source: Synthetic
Product namePitstop® 1 - negative control, Negative control for clathrin inhibitor Pitstop® 1
DescriptionNegative control for clathrin inhibitor Pitstop® 1 (ab120685)
Negative control for clathrin inhibitor Pitstop® 1 (ab120685) which is of the same chemical class and has a highly related structure to Pitstop® 1. Inhibits amphiphysin binding to the clathrin TD with an IC50 >100 μM and does not block receptor-mediated endocytosis at concentrations of up to 300 μM (unpublished reports).
General notesSold under exclusive licence from Children's Medical Research Institute and Newcastle Innovation Ltd. Pitstop® is a trademark of Freie Universitat Berlin, Newcastle Innovation Ltd. and Children's Medical Research Institute
Chemical name2-(4-Aminobenzyl)-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinoline-6-sulfonic acid potassium salt
Storage instructionsStore at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months.
Solubility overviewSoluble in DMSO to 100mM and in water to 25mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab120686 has been referenced in 1 publication.
- Liu Y et al. Extracellular ATP drives breast cancer cell migration and metastasis via S100A4 production by cancer cells and fibroblasts. Cancer Lett 430:1-10 (2018). PubMed: 29733962